Researchers are studying a group of 80 dogs with osteosarcoma to generate comparison data for ongoing and future studies of new chemotherapeutic agents.
Displaying 1 - 10 of 72 results
Xanadu, a fun-loving Labrador retriever, was diagnosed with osteosarcoma of his right front leg in August 2010. Lisa Dowell chronicled her dog’s ensuing struggle in...
Osteosarcoma is the most common primary bone tumor of dogs, with 10,000 new diagnoses each year. 1 It is most commonly diagnosed in large and...
Researchers are investigating the effectiveness of a novel immunotherapy to help reduce metastatic disease (cancer spread) and prolong quality of life in dogs with osteosarcoma.
Researchers will investigate the role of a signaling pathway in the progression of bone cancer in dogs and evaluate its potential as a new therapeutic target to help treat this disease.
Researchers will explore metabolic drivers of cancer growth and look for new therapy targets for osteosarcoma, the most common type of bone cancer in dogs.
Researchers are evaluating the effectiveness of oral rapamycin as an adjunct, postsurgery therapy to combat cancer spread (metastasis) in client-owned dogs.
This study will characterize the expression of toll-like receptors, which activate the immune system, in canine osteosarcoma cells to better determine the biological consequences associated with activating these receptors.
Researchers will investigate how osteosarcoma spreads, in the hopes of finding new treatment targets.
This study will provide a molecular framework for understanding the process of miR-9-driven tumor spread in canine osteosarcoma, thereby generating potential new targets for therapy to prevent or treat tumor spread in this devastating disease.